Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN

Abstract

Vedolizumab was safe and effective in this cohort of paediatric refractory IBD. These data support previous findings of slow induction rate of vedolizumab in CD and a trend to be less effective compared with patients with UC.

Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease

“…176 The retrospective case reports of pediatric patients with IBD found that vedolizumab tended to be slower acting and have lower remission rates in patients with CD compared to those with ulcerative colitis. 177,178 Long-term, open-label follow-up data report low rates of infusion reactions, serious infections, and malignancy. 179,180 The consensus group did not make a recommendation for or against the use of vedolizumab in patients who had failed prior anti-TNF therapy.…”

Response to vedolizumab for children with steroid‐refractory Ulcerative Colitis unresponsive to anti‐TNF

“…Ledder et al. on behalf of the ESPGHAN Porto group report 41 children; 33 had UC,and 8 had IBD‐Unclassified . Median PUCAI for these 41 children was 45 at start of treatment, and all had received anti‐TNF.…”

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases

“…ESPGHAN recently published the largest multicenter case series of 64 children, mean 14.5 (range 2–18) years old and treated with vedolizumab. No serious drug‐related AEs were reported at a median follow up of 24 weeks (IQR 14–38, range 6–116) …”

“…No serious drugrelated AEs were reported at a median follow up of 24 weeks (IQR 14-38, range 6-116). 30 Elderly. Post hoc analysis of the GEMINI 1 and 2 trials was performed, with patients stratified by age into <35, 35-54, and > 55 years old.…”